Women's Health

Investigators develop a genetic-risk score to identify those who would benefit most from lifestyle counseling to prevent the condition.

Findings show that key factors include age, infecting variant, underlying illnesses, and vaccination status.

Legislation allowing pharmacists to prescribe contraceptives is becoming more widespread.

Osteseconazole (Vivjoa) is the first FDA-approved treatment for recurrent vulvovaginal candidiasis, also known as chronic yeast infection, in women with a history of the condition who are not of reproductive potential.

TherapeuticsMD, Inc has submitted a supplemental New Drug Application for estradiol and progesterone capsules 0.5 mg/100 mg (Bijuva) to the FDA.

On this week's episode, Suzy is joined by Michelle Henry, MD, from Skin & Aesthetic Surgery of Manhattan, a board-certified dermatologist located in New York.

32 public colleges with combined enrollment of more than 700,000 students must comply with law by January 2023.

Premsyn PMS temporarily relieves symptoms associated with premenstrual syndrome.

Getting an appointment with an infectious diseases specialist, particularly after giving birth and while managing a chronic disorder, such as substance use, is difficult, investigators say.

21-gene profiling is also preferred for patients with 1 to 3 pathologically positive lymph nodes, according to a presentation at the Hematology/Oncology Pharmacy Association conference.

They are also at greater risk of death than men when undergoing cardiac procedures, a new analysis shows.

Pembrolizumab (Keytruda) approved as a single agent for the treatment of patients with microsatellite instability–high or mismatch repair deficient advanced endometrial carcinoma.

Our first on-location podcast episode featuring 2 prolific women in the pharmacy world!

Only 40% of patients with platinum sensitive disease are receiving a PARP inhibitor in the first-line setting.

Data from the SOLO-1 trial highlight that even with an excellent prognostic group, patients with ovarian cancer still benefit from the use of a PARP inhibitor.

The death rate from cervical cancer has dropped by more than 50% since 1975.

Use of mirvetuximab soravtansine monotherapy in patients with ovarian cancer resulted in meaningful anti-tumor activity, consistent safety, and favorable tolerability.

Pharmacists are essential partners in solving overspending caused by dose-specific packaging of lenvatinib.

Black women are at an increased risk of dying from cancer of any type compared to White women, but gynecologic cancers have some of the widest survival gaps.

Hormone replacement therapy can improve quality of life without necessarily increasing the risk of recurrence.

Although poorer prognoses are common for all patients with advanced and recurrent endometrial cancers, minority populations are disproportionately affected with higher rates of mortality.

Lenvatinib was approved in July of 2021 for the treatment of microsatellite-stable advanced endometrial cancer after platinum-based chemotherapy.

Speakers at the annual Society of Gynecologic Oncology annual meeting emphasized the theme of building bridges and breaking barriers to advance gynecologic care.

S. Diane Yamada, MD, president of the Society of Gynecologic Oncology (SGO), discusses some key developments in the field of gynecologic oncology that will be on the agenda at the SGO 2022 annual meeting.

The medications may also help tackle the global problem of antibiotic resistance, investigators say.